用高吞吐率虚拟查和分子动力学模拟来识别用于阿尔茨海默病的stigmasterol衍生的ACHE抑制剂
M Oliur Rahman1, Sheikh Sunzid Ahmed2, Ali S Alqahtani3
1Department of Botany, Faculty of Biological Sciences, University of Dhaka, Dhaka, 1000, Bangladesh. oliur.bot@du.ac.bd.
Scientific reports
|October 21, 2025
概括
研究人员从斯蒂格马斯托罗尔类似物中确定了强有力的阿尔茨海默病 (AD) 候选药物. 这些化合物显示出作为乙胆酶 (AChE) 抑制剂的前景,为AD治疗提供了潜在的新途径.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 计算机化药物发现技术
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 目前的AD疗法提供症状缓解,但缺乏治愈潜力,并可能产生副作用.
- 斯蒂格马斯特是一种植物,表现出神经保护性质,表明其类似物是AD的潜在治疗剂.
研究的目的:
- 来识别用于阿尔茨海默氏病 (AD) 治疗的新型乙胆酶 (AChE) 抑制剂从树脂醇类似物中.
- 评估潜在候选药物的结合亲和力,药理动力学特性和毒性.
- 为开发新的AD疗法提供计算基础.
主要方法:
- 972种斯蒂格马斯托罗尔类似物 (SAs) 的高通量虚拟选.
- ADMET过,分子动力学 (MD) 模拟,MM/GBSA和DFT计算.
- 对化合物的结合相互作用,稳定性和反应性的分析.
主要成果:
- 三种化合物 (SA4,SA12,SA15) 与stigmasterol和donepezil相比,对AChE表现出更高的结合亲和力.
- 药理动力学和毒性评估表明,已识别的SAs具有有利的特性.
- MD模拟和MM/GBSA计算证实了SA4,SA15和SA12的稳定性和功效.
结论:
- 斯蒂格马斯托罗尔类似物显示出作为阿尔茨海默病 (AD) 的ACHE抑制剂的显著潜力.
- 已识别的化合物 (SA4,SA15,SA12) 具有有利的结合特性和类似药物的特性.
- 这些发现为进一步的实验室和体内验证作为新型AD治疗药物的斯蒂格马斯托罗尔类似物奠定了基础.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
1.2K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
相关概念视频
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
